BR Biopharma (NASDAQ:BRBI – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.05 EPS for the quarter, FiscalAI reports. The firm had revenue of $23.80 million for the quarter.
BR Biopharma Price Performance
Shares of BRBI stock traded up $0.06 during trading on Thursday, hitting $7.24. 200 shares of the stock traded hands, compared to its average volume of 3,672. BR Biopharma has a 52-week low of $6.87 and a 52-week high of $16.61. The firm has a market capitalization of $85.50 million, a P/E ratio of 90.50 and a beta of 0.43. The firm’s fifty day moving average price is $11.61 and its 200-day moving average price is $12.63.
BR Biopharma Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Monday, August 17th were given a dividend of $0.1415 per share. The ex-dividend date was Monday, August 17th. This is a decrease from BR Biopharma’s previous quarterly dividend of $0.1470. This represents a $0.57 annualized dividend and a yield of 7.8%. BR Biopharma’s dividend payout ratio (DPR) is 525.00%.
Analyst Ratings Changes
Several research firms recently weighed in on BRBI. Weiss Ratings raised shares of BR Biopharma from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Citigroup lowered BR Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce”.
Check Out Our Latest Research Report on BRBI
About BR Biopharma
BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.
Featured Stories
- Five stocks we like better than BR Biopharma
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
